# A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus

> **NCT03985293** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 412 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo
- **DRUG:** PF-06882961

## Key facts

- **NCT ID:** NCT03985293
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-15
- **Primary completion:** 2021-06-08
- **Final completion:** 2021-07-07
- **Target enrollment:** 412 (ACTUAL)
- **Last updated:** 2022-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03985293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03985293, "A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03985293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*